In the BioHarmony Drug Report Database

"Preview" Icon

Berotralstat

Orladeyo (berotralstat) is a small molecule pharmaceutical. Berotralstat was first approved as Orladeyo on 2020-12-03. It has been approved in Europe to treat hereditary angioedemas. It is known to target plasma kallikrein. Orladeyo’s patents are valid until 2039-11-01 (FDA).

 

Trade Name

 

Orladeyo
 

Common Name

 

berotralstat
 

ChEMBL ID

 

CHEMBL4594271
 

Indication

 

hereditary angioedemas
 

Drug Class

 

Enzyme inhibitors

Image (chem structure or protein)

Berotralstat structure rendering